Sleep as Foundation.
Performance as Purpose.

REMz is developing a non-invasive neurostimulation device for sleep.

Problem

Alleviating sleep disruption is a major unmet need across multiple population demographics.

Our primary focus is on people experiencing menopause seeking non-pharmaceutical options. Our secondary focus is on people looking to optimize and support performance in athletics and everyday life.

  • Sleep deprivation costs the US economy $411 Billion USD alone. Global Wellness Institute

  • 40-60% of those experiencing peri- and menopause have sleep challenges, translating to an approximate Total Addressable Market of over 25 million individuals in the UK and North America alone.

Approach

REMz is developing an intraoral neurostimulation approach intended for short duration, pre-sleep use.The concept is designed to be non-invasive, non-pharmaceutical, and consumer-friendly, with REMz-specific performance to be established through planned testing and clinical development.Pursuing a Q-Sub-guided 510(k) strategy with parallel UK regulatory planning using existing market precedents.

Why Now?

There is a large unmet need to improve sleep, particularly for populations such as those experiencing menopause and those looking to optimize recovery. The clinical and regulatory rationale is well-supported by a growing number of precedent neurostimulation devices and rapidly building demand for non-invasive, at-home solutions.

The Team

REMz has a highly capable founder team with decades of experience across multi-national device, pharmaceutical, and biotech companies. Our skill-set includes specialized experience in product launch, regulatory, and reimbursement. Combined with a world-class expert in neurostimulation, REMz is on a path to change sleep forever.

founders (at) remzsleep . (com)

REMz is a development-stage product concept. Statements on this website describe development plans, market focus, scientific rationale, and regulatory strategy. Product performance, claims, and any future indications remain subject to validation and regulatory review.